Press release
Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.
The data seems impressive - an extraordinary 78% of patients treated with PL8177 achieved clinical response compared to just 33% for placebo, with statistical significance (p
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) here
News-ID: 3947959 • Views: …
More Releases from ABNewswire
Blue Ocean Life Brings Ocean-Inspired Calm, Resilience, and Freedom to Everyday …
Blue Ocean Life Company LLC spreads a message of healing, balance, and coastal calm through its mission-driven apparel and lifestyle brand. With designs like "Saltwater Heals Everything" and "Find Your Calm," the Cape Cod-based company blends style with purpose, reminding people of the restorative power of the ocean while addressing rising mental health challenges through lifestyle design.
CAPE COD, Mass. - Blue Ocean Life Company LLC is spreading a message of…
Third Hemisphere Strengthens Position as Leading Investment Communications Speci …
Jeremy Liddle [https://thirdhemisphere.agency/about-us] Third Hemisphere has established itself as a specialist in alternative investment communications, expanding capabilities across private credit, growth equity, and venture capital. The agency's regional positioning reflects the increasing sophistication of the Asia-Pacific investment landscape, where institutional allocators are diversifying beyond traditional public markets into private and alternative asset strategies.
The alternative investment environment in the region demands communications expertise that integrates financial understanding, Third Hemisphere, a full…
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure.
Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is…
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business.
KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus.
Each collection features 30 professionally produced instrumental tracks, available in both WAV…
More Releases for Palatin
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), Del …
The Key Moderate Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Moderate Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate Dry Eye pipeline products will significantly revolutionize the Moderate Dry Eye market dynamics.
DelveInsight's "Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palati …
The Key Mild Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Mild Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.
DelveInsight's "Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Pal …
The Key Dry Eye Disease Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding…
Dry Eye Disease Market to Expand Significantly by 2034, States DelveInsight Repo …
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye…
Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Resu …
Palatin Technologies (NYSE: PTN)* and their latest developments: Palatin's Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside results from ulcerative colitis trial; Only Oral Option in Market Currently Dominated by Injections Uniquely Positioning Palatin
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan…
Dry Eye Disease Market to Show Incremental Growth, asserts DelveInsight | Promin …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted…
